Financial reports
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
12 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
Current reports
8-K
Cost Associated with Exit or Disposal Activities
12 Apr 24
8-K
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29 Mar 24
8-K
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28 Mar 24
8-K
Termination of a Material Definitive Agreement
15 Mar 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
27 Oct 23
8-K
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
28 Sep 23
8-K
Other Events
31 Aug 23
8-K
Molecular Templates Announces 1-for-15 Reverse Stock Split
11 Aug 23
Registration and prospectus
S-3
Shelf registration
25 Apr 24
S-8
Registration of securities for employees
29 Mar 24
S-3
Shelf registration
10 Aug 23
D
$90.74 mm in equity / options / securities to be acquired, sold $20.00 mm, 19 investors
31 Jul 23
S-8
Registration of securities for employees
3 Apr 23
S-8
Registration of securities for employees
29 Mar 22
S-8
Registration of securities for employees
19 Mar 21
424B5
Prospectus supplement for primary offering
18 Feb 21
424B5
Prospectus supplement for primary offering
17 Feb 21
424B5
Prospectus supplement for primary offering
17 Aug 20
Proxies
DEFA14A
Additional proxy soliciting materials
12 Sep 23
DEF 14A
Definitive proxy
12 Sep 23
DEF 14A
Definitive proxy
18 Jul 23
PRE 14A
Preliminary proxy
30 Jun 23
DEF 14A
Definitive proxy
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
7 May 20
DEF 14A
Definitive proxy
23 Apr 20
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
Other
EFFECT
Notice of effectiveness
21 Aug 23
UPLOAD
Letter from SEC
16 Aug 23
CORRESP
Correspondence with SEC
16 Aug 23
EFFECT
Notice of effectiveness
18 Aug 20
CORRESP
Correspondence with SEC
13 Aug 20
UPLOAD
Letter from SEC
12 Aug 20
EFFECT
Notice of effectiveness
19 Jun 20
CORRESP
Correspondence with SEC
17 Jun 20
CORRESP
Correspondence with SEC
16 Jun 20
UPLOAD
Letter from SEC
16 Jun 20
Ownership
4
BIOTECH AG BB
4 Apr 24
4
KEVIN M. LALANDE
4 Apr 24
SC 13D/A
SANTE HEALTH VENTURES I LP
2 Apr 24
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
4
Maurizio Voi
25 Jan 24
4
Jason S. Kim
25 Jan 24